Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug enters early human safety testing

NCT ID NCT07232732

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Nov 18, 2025 · Last updated May 09, 2026 · Updated 22 times

Summary

This early-stage study tests the safety and how the body handles a new drug called LY3549492 in 120 healthy adults who are overweight or have obesity. Participants will receive multiple doses of the drug and be monitored for about 8 weeks. The goal is to see if the drug is safe and tolerable, not to treat or cure obesity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fortrea Clinical Research Unit

    RECRUITING

    Daytona Beach, Florida, 32117, United States

    Contact Phone: •••-•••-••••

    Contact

  • Fortrea Clinical Research Unit

    RECRUITING

    Dallas, Texas, 75247, United States

    Contact Phone: •••-•••-••••

    Contact

  • Fortrea Clinical Research Unit

    COMPLETED

    Madison, Wisconsin, 53704, United States

Conditions

Explore the condition pages connected to this study.

HEALTHY OBESITY OVERWEIGHT